# OnCo record nct05024214 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05024214/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05024214", "NCT05024214" ;
  schema:name "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Lenvatinib, Envafolimab, Sunitinib in non-small-cell lung cancer and small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05024214/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05024214> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-11-15" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/hcc/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/envafolimab/>, <https://onco.cc/drugs/sunitinib/> ;
  onco:companies <https://onco.cc/companies/3d-medicines/> .